Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer

Medicine and Dentistry

• Pancreas Cancer 100%
• Poly ADP Ribose Polymerase 100%
• Fibroblast Growth Factor Receptor 1 100%
• Pancreas Adenocarcinoma 58%
• 1 Tert Butyl 3 [6 (3,5 Dimethoxyphenyl) 2 (4 diethylaminobutylamino)pyrido[2,3 D]pyrimidin 7 Yl]urea 33%
• Combination Therapy 25%
• Olaparib 25%
• Protein Expression 16%
• Cell Viability 16%
• Lethality 16%
• Adenocarcinoma Cell Line 16%
• PARP Inhibitor 16%
• Gene Expression 8%
• Adjuvant Therapy 8%
• Low Drug Dose 8%
• Chemotherapy 8%
• Western Blot 8%
• Immunoreactivity 8%
• Immunofluorescence 8%
• Cancer Chemotherapy 8%
• Tumor Xenograft 8%
• Docking (Molecular) 8%
• Maintenance Therapy 8%
• Monotherapy 8%
• Protein Bcl Xl 8%
• Procaspase 9 8%
• PARP1 8%
• Cell Line 8%
• Cytotoxicity 8%
• Dasatinib 8%
• Caspase 3 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase 100%
• Pancreas Cancer 100%
• Fibroblast Growth Factor Receptor 1 100%
• Pancreas Adenocarcinoma 58%
• 1 Tert Butyl 3 [6 (3,5 Dimethoxyphenyl) 2 (4 diethylaminobutylamino)pyrido[2,3 D]pyrimidin 7 Yl]urea 33%
• Olaparib 25%
• Combination Therapy 25%
• Cell Viability 16%
• Lethality 16%
• Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor 16%
• Cytotoxicity 8%
• Western Blot 8%
• Chemotherapy 8%
• Dasatinib 8%
• Protein Bcl Xl 8%
• Procaspase 9 8%
• Neoplasm 8%
• Caspase 3 8%
• Monotherapy 8%